Ann: Quarterly Activities Report and Appendix 4C, page-128

'The TK' strategy of throwing as much mud against the wall as possible and seeing what sticks. Unfortunately, for us long suffering (many ex like myself) believers, nothing has stuck.

Everything about this 'rapid commercialization ' stinks - from the third rate partners; Phenix, Ilara, WMA, diabeties Queensland to Any real player runing; RB, Sanofi, Docs without Borders, DARPA (maybe???).

Developing a second (Sleepcheck) and third (suspicious handheld device) product before the first went to market were red flags for me at the time but I choose to swim outside the flags. It's clear evidence decision makers knew there was no demand for the product or lacked strategic/commercial acumen.

The entire journey has been marked by unanswered questions and unclear market releases (how many retractions/clarifications have there been within over the years?). Whats going on with the respiratory clinic or DARPA, not to mention when deadlines slipped and we got 'oh yeah, we scrapped that deal'.

To Roger Ashton, I've heard your voice once and it was to chair an AGM. My old work boots have more charisma and would do a better job at selling. It's a shame that retailers dominate the register and there wasn't a body with enough interest to send this leadership team to where they belong - that is the discard pile.

There needs to be some real change at the top, a proper consolidation of products ( sell SleepCheck) and focus on getting this thing into Telehealth. But it'll be a slog